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Abstract Oral cancer represents a common entity com-
prising a third of all head and neck malignant tumors. The
options for curative treatment of oral cavity cancer have
not changed signiﬁcantly in the last three decades; how-
ever, the work up, the approach to surveillance, and the
options for reconstruction have evolved signiﬁcantly.
Because of the profound functional and cosmetic impor-
tance of the oral cavity, management of oral cavity cancers
requires a thorough understanding of disease progression,
approaches to management and options for reconstruction.
The purpose of this review is to discuss the most current
management options for oral cavity cancers.
Keywords Neck dissection  Oral cavity cancer 
Prognosis  Treatment
Introduction
Cancer of the oral cavity comprises nearly 30% of all
malignant tumors of the head and neck. Approximately
90% of cases are squamous cell carcinomas [1] while the
remaining 10% represent rare malignancies (unusual forms
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DOI 10.1007/s00405-010-1206-2of squamous cell carcinoma, minor salivary gland tumors,
melanomas, lymphomas, sarcomas) and a variety of
malignant tumors of odontogenic origin. In North America,
common risk factors for the development of cancer of the
oral cavity include tobacco and alcohol use. Outside of
North America, dietary habits, such as chewing betel and
areca nuts present additional risks for the development of
oral cancer. Beyond these risks, there is not much evidence
linking dietary factors or nutritional deﬁciencies to the
development of oral cavity cancer. The highest rates of
incidence of cancer of the oral cavity occur in Pakistan,
Brazil, India and France [2].
Although the use of alcohol and tobacco are independent
risk factors for the development of oral cavity cancer, the
synergistic effect of these two factors has been well doc-
umented [3]. It has been suggested that the use of alcohol
suppresses DNA repair following exposure to nitrosamine
compounds; however, the exact mechanism of the observed
synergy remains poorly deﬁned.
Human papillomavirus (HPV) is strongly associated
with development of oropharyngeal cancers and a small
minority of oral cavity cancers [4]. Over the past 30 years,
the proportion of potentially HPV-related oral cancer in the
United States has increased, an increase possibly related to
changing sexual behaviors [5]. However, the exact inci-
dence of HPV-related head and neck cancers, other than
oropharyngeal cancers, remains subject to debate and may
depend on epidemiological factors as well as technical
improvements in the detection of HPV [6], but may also be
due to misclassiﬁcation of cancers of the base of tongue as
oral cancers instead of oropharyngeal cancers. The asso-
ciation between index and second primary anogenital and
oral cavity/pharyngeal cancers, strongest in never-married
men, supports the inﬂuence of sexual behaviors on the risk
of HPV-associated head and neck cancers [7].
Poor dental hygiene and chronic mechanical irritation
have also been associated with the development of cancer
of the oral cavity. When the lateral aspect of the oral
tongue is exposed to mechanical friction as a result of a
sharp tooth edge or irritation of the oral cavity from an ill-
ﬁtting denture, a cascade of events beginning with chronic
irritation may lead to the development of squamous cell
carcinoma. However, other, unknown factors may play a
role in the association between poor dental hygiene,
mechanical friction and the development of oral cancer [8].
During the last decade, a number of studies have dem-
onstrated the signiﬁcant role of genetic instability in the
etiology of cancer of the oral cavity [9]. Genetic suscep-
tibility may account for the development of oral cancer in
non-smokers and drinkers and in young adults, but the
precise mechanisms remain to be elucidated [10]. In
addition, since 1930, the incidence of tongue cancer in
young women has more than doubled and such ﬁndings
strongly suggest an environmental and/or a genetic pre-
disposition to the development of cancer of the oral cavity.
During the past 30 years, there has been an explosion of
knowledge of different aspects of oral cancer. Neverthe-
less, despite these developments, the 5-year overall sur-
vival of this disease has advanced little, although the
quality of life of patients has undoubtedly improved [11].
Although there are signiﬁcant limitations to the current
staging system of oral cavity cancer, it is clear that early
identiﬁcation, diagnosis and management of oral cavity
cancer result in improved patient outcomes.
Unlike other areas of the aerodigestive tract, the oral
cavity is accessible and easily examined, and as a result,
screening may be considered in an effort to identify early
cancers. Early detection and recognition of malignant and
premalignant lesions in the oral cavity require awareness of
relevant complaints and symptoms among dentists and
general practitioners, as most patients will initially visit
these professionals with their complaints or symptoms.
Lesions, such as leukoplakia and erythroplasia need to be
evaluated with appropriate biopsy, excision, or close
monitoring. Primary screening may be done under the care
of a primary care practitioner, dentist or head and neck/oral
surgeon. Organized screening clinics could be helpful in
evaluating suspicious lesions in the oral cavity.
Biological behavior
Oral cavity cancer develops through a series of molecular
changes reﬂected as histopathological stages: through mild
(low grade), moderate and severe (high grade) dysplasia to
carcinoma in situ and then invasive disease [12]. The
grading or classiﬁcation of these premalignant or early
malignant lesions is still a matter of much debate [13].
Early detection of oral lesions that will develop into
invasive tumors is necessary to improve the prognosis of
patients with oral cancer. However, which intraepithelial
lesions will progress to invasive cancer and which will not
is the subject of extensive research.
The white patches are often associated with premalig-
nant lesions, and are commonly referred to as ‘‘leukopla-
kia.’’ Leukoplakia, however, is not a pathologic diagnosis.
The white patches usually represent hyperkeratosis, which
may or may not be associated with atypia. Hyperkeratosis
without atypia is not premalignant, while atypia without
hyperkeratosis, often appearing clinically as erythroplasia,
is premalignant. Waldron and Shafer [14] reviewed 3,256
tissue specimens clinically diagnosed as leukoplakia.
Microscopic study showed that 80.1% were varying com-
binations of hyperorthokeratosis, hyperparakeratosis, and
acanthosis without epithelial dysplasia. Mild to moderate
dysplasia was noted in 12.2% of specimens, and severe
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Inﬁltrating squamous cell carcinoma was diagnosed in only
3.1% of specimens submitted with a clinical diagnosis of
leukoplakia.
Prognostic indicators
There are number of prognostic factors that determine the
survival of patients and affect treatment decisions. The
basic prognostic factors are tumor size (T-stage), regional
nodal involvement (N-stage) and the presence or absence
of distant metastasis (M-stage). This TNM classiﬁcation is
still used today with various modiﬁcations. Several other
biological, molecular and histopathologic parameters have
also been identiﬁed during the last decades. The prognosis
of a patient suffering from oral cavity cancer is also
associated with patient co-morbidity, performance status,
nutritional status and immunity. Although age itself is not a
prognostic indicator, co-morbidities that are commonly
associated with advanced age may represent a negative
prognostic predictor.
A series of histopathological features may have signiﬁ-
cant impact on the prognosis of oral cavity cancers. The
presence of perineural invasion, lymphocytic response and
depth of invasion are examples of histopathological
parameters not accounted for in the current AJCC/UICC
staging system. In addition, extracapsular spread (ECS),
which may be associated with a 50% reduction in survival,
may have a signiﬁcant impact on the prognosis of patients
with regional disease [15].
Among other parameters particularly predictive of nodal
metastasis and therefore prognosis, tumor thickness has
been associated with local recurrence and survival for
cancer of the oral tongue [16]. The exact depth of invasion
and correlation with survival is not clear; however, several
studies have suggested that tumor thickness greater than
4.0 mm signiﬁcantly increases the risk for cervical
metastases and, therefore, has a negative impact on sur-
vival [17]. Other studies have suggested that greater than
5.0 mm depth is associated with an increased rate of
regional disease [18]. Currently, most surgical oncologists
feel that tumor thickness of 4.0 mm or greater is associated
with an increased risk for regional metastases and as a
result recommend elective treatment of the clinically N0
neck even in the absence of other high-risk histopatholo-
gical features. Recently, Patel et al. [19] have demonstrated
that patients with thick tumors have a high risk of nodal
metastases, supporting the liberal use of elective neck
dissection in these patients, despite clinically negative
necks. However, it is important to point out that these
recommendations were established in retrospective studies,
and in the context of elective neck dissection. The routine
histopathologic evaluation of neck dissection specimens
has been shown to be insufﬁcient for accurate detection of
micrometastases. The more sections taken from each
lymph node, the more occult disease will be detected [20].
In a recent paper by Goerkem et al. [21], all known
histopathologic parameters thought to predict occult lymph
node metastases have been reevaluated within the context
of sentinel lymph node biopsy (SLNB). In this study,
neither tumor depth nor tumor thickness was predictive for
occult disease. The only parameters signiﬁcantly associated
with the occurrence of occult disease were lymphovascular
invasion, poor grading and a dissolute invasion pattern at
the tumor front. The authors concluded that any squamous
cell carcinoma of the oral cavity should undergo elective
neck treatment, preferably by SLNB, irrespective of the
measured tumor depth or tumor thickness. These results
were subsequently conﬁrmed by the studies of Bilde et al.
[22] and Alkureishi et al. [23].
High-risk histopathological features that inﬂuence the
risk of local regional recurrence include angioinvasion,
lymphatic emboli and perineural invasion. However, the
most signiﬁcant prognosticator in oral cancer is the pres-
ence of ECS of lymph node metastases [24–27]. Because
the presence of ECS has been identiﬁed as an indicator of
poor prognosis, patients with ECS are commonly treated
with adjuvant therapy, including radiotherapy and chemo-
radiotherapy. Yet, despite adjuvant therapy, one-third of
patients will experience regional recurrence [25].
Brandwein-Gensler et al. [28] have published a risk-
scoring system that incorporates tumor pattern of invasion
which is strongly and independently predictive of local
disease free and overall survival in oral cancer. These
efforts and others requiring validation will likely result in
improved patient management decisions.
Diagnosis and evaluation of local disease
The initial evaluation of a patient with suspected oral
cavity cancer can be relatively straightforward. A complete
history, including the use of alcohol, tobacco and dietary
habits as well as oral hygiene should be documented.
Because the oral cavity is readily accessible, changes in the
mucosa are easily identiﬁed and evaluated. Although brush
biopsy has recently been used in the dental community as a
screening tool, several studies suggest that the sensitivity
and speciﬁcity of this technique is unacceptably low [29,
30]. A surgical biopsy represents the most reliable method
of diagnosis and provides the pathologist with tissue
architecture necessary to make a deﬁnitive diagnosis of
invasive carcinoma.
The diagnosis of invasive carcinoma mandates a thor-
ough evaluation to assess the extent of tumor. To delineate
Eur Arch Otorhinolaryngol (2010) 267:1001–1017 1003
123the tumor and adjacent premalignant mucosa more pre-
cisely, ﬂuorescence may be helpful. The use of ﬂuores-
cence imaging may be helpful in the detection of
premalignant changes and determination of the extent of
the pathologically changed mucosa [31].
Once a deﬁnitive diagnosis has been obtained, imaging
is essential to determine the stage of the tumor and pres-
ence of metastasis. Although uncommon on initial pre-
sentation, the presence of distant metastasis as well as
second primary cancers of the upper aerodigestive tract
should be evaluated by physical examination and either
chest radiography or computed tomography (CT).
Although extensive lesions may be heralded by trismus,
otalgia or hyperesthesia, the lack of these symptoms does
not preclude invasion of the surrounding structures. CT
with administration of intravenous contrast offers an initial
assessment of soft tissue, bone and mucosal involvement. If
there is concern regarding the invasion of the deep soft
tissue, muscle or nerve, a magnetic resonance imaging
(MRI) study may prove more accurate. MRI is ideal for the
evaluation of soft tissue and in some cases, nerve
involvement, but it may be helpful in determining bone
invasion as well. Enhancement of the lingual, alveolar or
trigeminal ganglion may suggest perineural involvement.
The MRI scan is particularly helpful in the evaluation of
non-epidermoid carcinoma (i.e. adenoid cystic carcinoma)
in which perineural invasion is frequent. The overall
accuracy of CT and MRI for T-staging is comparable [32].
However, CT is more affected by artifact caused by dental
metals, whereas MRI is more affected by artifact caused by
movements of the patient. Superﬁcial lesions are often not
demonstrated by either modality and additional imaging
appears superﬂuous in these cases.
Diagnosis and evaluation of mandibular invasion
The mandibular cortex may be involved by adherence or
direct extension of the tumor, or the medullary cavity may
be involved in a more extensive manner by deeply pene-
trating tumor, in which case there may be far more bone
involvement than is apparent on the surface. Plain radi-
ography has been used extensively in the past, and is rea-
sonably accurate for the diagnosis of medullary tumor
invasion of the mandible; however, subtle changes asso-
ciated with the cortex are more difﬁcult to identify. The
introduction of panoramic radiography, CT, MRI and bone
scintigraphy with single photon emission computed
tomography (SPECT) have increased the accuracy of pre-
operative imaging and staging.
Signiﬁcant debate still exists regarding the optimal
modality or combination of modalities recommended for
preoperative assessment. In general, bone involvement is
usually underestimated by CT, whereas with MRI and bone
scintigraphy with SPECT the involvement is often over-
estimated [33, 34]. A negative MRI or bone scan excludes
mandibular invasion in all likelihood.
For bone involvement of the retromolar trigone, the
sensitivity of CT is approximately 50% with a negative-
predictive value of 60%. However, the positive-predictive
value is approximately 90%. Thus, while the CT scan is
accurate when bone erosion is clearly identiﬁed, its nega-
tive-predictive value is unacceptably low and, therefore, is
an inaccurate indicator of bone invasion at the retromolar
trigone [35]. CT renders an excellent view of both the soft
tissue and bone of the mandible, however, it has several
limitations, the most signiﬁcant being artifact caused by
dental metals, which can obscure invasion of the mandib-
ular cortex. In addition, CT may misleadingly detect
defects in the cortex resulting from irregularly shaped
alveoli or by or periapical disease.
In light of these shortcomings, several investigators have
reported on the use of a Dentascan. The Dentascan was
introduced in the early 1980s to assist oral maxillofacial
surgeons in planning for osseointegrated implants. The
images are derived by reformatting standard axial CT scans
in two views, panelliptical and parasagittal. This refor-
matting permits assessment of the buccal and lingual cor-
tices. The diagnostic accuracy of the Dentascan for
mandibular invasion is high, yielding a sensitivity of 95%,
and a speciﬁcity of 79% with a positive-predictive value of
87% and a negative-predictive value of 92% [36]. The
Dentascan is, therefore, an accurate method for preopera-
tive evaluation of mandibular invasion in patients with
squamous cell carcinoma of the oral cavity.
Although CT and Dentascan may offer excellent meth-
ods for assessing bone, MRI offers the additional advan-
tage of imaging soft tissue, and potentially the medullary
bone space. Several studies have examined the use of MRI
in assessing mandibular invasion, and it has been con-
cluded that MRI is superior for evaluating the medullary
space of the mandible, but inadequate for assessing man-
dibular invasion [37]. Shaha [38] examined the value of
various studies, including panoramic radiographs, dental
ﬁlms, routine mandible ﬁlms, bone scans, CT and MRI and
found that CT was not very helpful mainly because of the
presence of irregular alveoli and artifacts. Others have
studied the combination of several diagnostic tools to
assess mandibular invasion and suggested the use of a
combination of CT or MRI with SPECT bone scintigraphy
[39].
Clinical evaluation is essential for determining the
presence of bone invasion and the optimal method of
resection, marginal versus segmental [40]. Most centers
consider the combination of CT or MRI and a panoramic
radiography acceptable for preoperative imaging of the
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of bony invasion is probably determined at the time of
surgery. Unless there is frank invasion of the bony cortex,
periosteal stripping followed by frozen section examination
at the time of surgery is often the most reliable measure of
bone invasion. Recent studies have shown that technetium
(Tc) 99
m bone scintigraphy in the form of planar views or
as SPECT provide high diagnostic accuracy for mandibular
invasion by oral squamous cell carcinoma of the alveolus
in both edentulous and dentate patients [41, 42].
Among all evaluations of the extent of disease in the
oral cavity in relation to involvement of the mandible, it is
the authors’ opinion that the best investigation continues to
have a routine clinical evaluation and intraoperative eval-
uation of the proximity of the tumor to the inner border of
the mandible. However, preoperative assessment using
imaging techniques for planning and preparation of an
adequate surgical procedure including reconstruction will
be performed in most cases. A tendency to perform mul-
tiple investigations is revealed in the current literature [43].
Assessment of the neck
For the assessment of the lymph nodes in the neck, both
CT and MRI are used on a wide scale. The choice of
study is often determined by the imaging modality used
for evaluating the primary tumor. In general, the same
technique employed for imaging of the primary tumor is
used to stage the neck as well. Most studies that have
compared the accuracy of CT and MRI for the assessment
of the neck have found no signiﬁcant difference between
these two modalities [44, 45]. In studies reporting on the
important issue of accuracy of CT or MRI for the
assessment of the N0 neck, speciﬁcities and sensitivities
of CT and MRI vary considerably [44–47], but as a rule,
between 40 and 60% of all occult metastases are found
using either CT or MRI.
One of the main advantages of ultrasound (US) is that it
can easily be combined with ﬁne-needle aspiration biopsy
(FNAB) resulting in a speciﬁcity of 100% for the combined
technique of ultrasound guided ﬁne-needle aspiration
biopsy (UGFNAB). It was demonstrated to be accurate for
the evaluation of regional metastatic disease [44, 48].
Although the technique is not difﬁcult, considerable
training is required to successfully aspirate lymph nodes as
small as 5 mm and to select the most suspicious lymph
nodes from which to aspirate. In patients with a clinically
negative neck, the results of UGFNAB are less impressive,
as detection of lymph node metastasis by imaging tech-
niques requires a minimum size. UGFNAB identiﬁes
clinically occult metastases with a sensitivity of no more
than 48–73% [44, 47].
Fluorodeoxyglucose-positron emission tomography
(FDG-PET) enables the in vivo study of tissue metabolism.
FDG is an analog of glucose and its uptake reﬂects the
metabolism of the cell, which is increased in many tumors.
Disadvantages of FDG-PET are variable physiologic
uptake and the lack of anatomical detail. Another disad-
vantage is that FDG also accumulates in inﬂammatory
cells, such as granulocytes and hampers the differentiation
between tumor and inﬂammatory reactions. The accuracy
of the technique has been compared with conventional
diagnostic methods for pretreatment evaluation, therapy
response evaluation and relapse identiﬁcation [49, 50].
As mentioned before, the anatomical landmarks and
details on PET imaging are less well depicted than with CT
or MRI. The fusion of the more functional data of PET
images with the more anatomical information of CT in
particular has signiﬁcantly improved the interpretation of
the PET images [51]. However, the diagnostic accuracy for
detection of nodal metastasis does not seem to improve
much by the fusion of FDG-PET with CT as compared to
PET alone [52]. The main problems, limiting its accuracy
remain the poor anatomical resolution of the PET tech-
nique even after fusion with low dose, non-contrast CT and
the inability to reliably identify metastatic deposits under
5 mm. As a result, the reported sensitivity of PET or PET-
CT detection of lymph node metastases is similar to CT
and MRI and does not seem to add much to the use of these
modalities [50, 52–54]. As may be expected, a lower sen-
sitivity, ranging from 25 to 78% is reported for the N0 neck
[55–58].
Recent developments to improve the ability of MRI to
differentiate metastatic from benign cervical lymph nodes
include diffusion-weighted imaging, dynamic contrast-
enhanced MRI or the use of new (lymphotropic) contrast
agents as enhancers [59]. Diffusion-weighted magnetic
resonance imaging (DWI MRI) may be a helpful comple-
mentary tool to distinguish tumoral from non-tumoral tis-
sue, and a sensitivity and speciﬁcity for the detection of
nodal metastasis of 98 and 88%, respectively, have been
reported [60].
Dynamic contrast-enhanced MRI takes advantage of the
characteristics of the (metastatic) tumor as compared to
normal tissue by scanning the area of interest multiple
times starting before contrast, continuing through the
contrast phase and ending with the post-contrast phase. The
technique appears to be helpful in differentiating metastatic
from non-metastatic lymph nodes [61].
Ultra-small superparamagnetic contrast agents, such as
iron oxide particles (USPIO) accumulate in normal lymph
nodes because the particles are taken up by macrophages in
these nodes. Metastases do not take up the particles. The
uptake may accumulate over 6–24 h after administration of
the contrast agent. The use of these agents has been
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A sensitivity and speciﬁcity of up to 96 and 87%, respec-
tively, have been reported [63]. However, the costs and the
logistical problems associated with the need for delayed
imaging, 24–48 h after contrast injection, may prevent this
technique from gaining wide acceptance although it is
possible that a single acquisition could be sufﬁcient [64].
Furthermore, the need for highly T2-weighted images with
low-spatial resolution hampers the visibility of small
metastases and will result in a low sensitivity due to false-
negative results from the presence of undetected microm-
etastases [64].
Molecular markers as a diagnostic and prognostic tool
Several oral cancer biomarkers have recently been dis-
covered (alterations of p53, inactivation p16, overexpres-
sion of EGFR, etc.) Although many of these markers are
thought to have potential clinical interest, few of them are
being used in a clinical setting for oral cancer management.
Proteomic analysis by mass spectrometry is rapidly
advancing the ﬁeld of medical diagnostics because of its
ability to reliably identify proteins that are minimal in
concentration. These advancements have also beneﬁted
cancer biomarker research to the point where saliva is
now recognized as an excellent diagnostic medium for the
detection of malignant tumors of the oral cavity. Genomic
and proteomic studies of oral cancer tissues, plasma, and
saliva of oral cancer patients have allowed the identiﬁ-
cation of several cancer signatures with promising appli-
cation for diagnosis, prognosis and treatment. In addition,
methylation array analysis using saliva has allowed the
identiﬁcation of highly methylated gene loci with diag-
nostic and predictive value as a biomarker, with a sensi-
tivity of 62–77% and a speciﬁcity of 83–100% for oral
carcinoma [65]. Using subtractive proteomics, Hu et al.
[66] revealed several salivary proteins at differential
levels between the oral carcinoma patients and matched
control subjects. Five candidate biomarkers were suc-
cessfully validated and their combination yielded a sen-
sitivity of 90% and speciﬁcity of 83% in detecting oral
carcinoma.
As it is important to distinguish those intraepithelial
lesions that will progress to invasive cancer from those that
will not, it may be useful to have diagnostic tools for this
purpose. Different proteins have been studied as progres-
sion markers. Thus, podoplanin is highly expressed in oral
cancer and some oral premalignancies and has been found
to be an independent factor for oral cancer development by
multivariate analysis [67]. DNA content may also be a
relevant parameter in this respect and has been found to
correlate with the potential to progress to invasive cancer
[68]. Other genetic assays may be promising in distin-
guishing at-risk mucosal sites [69].
Nuclear expression of heterogeneous ribonucleoprotein
K increases signiﬁcantly from normal tissues to leukopla-
kia and malignancy, and may serve as a potential marker
for early diagnosis. Variance in cytoplasmic accumulation
can help in identifying a subgroup of patients with poor
prognosis [70]. On the other hand, informative RNA bio-
markers from the human serum transcriptome have been
successfully demonstrated for oral carcinoma detection; the
best combination of biomarkers yields a sensitivity of 91%
and a speciﬁcity of 71% [71].
Other biomarkers are related to prognosis, as occurs
with stratiﬁn whose overexpression is correlated with
reduced disease-free survival [72]. Similarly, CTTN
ampliﬁcation is associated with recurrence and reduced
disease-speciﬁc survival and may serve as a valuable bio-
marker to identify patients with tumors at high risk of
recurrence and poor outcome [73].
The gene expression proﬁle of patients with oral tongue
carcinoma has been analyzed, and three genes (GLUT3,
HSAL2 and PACE4) have correlated with different clinical
parameters, but only GLUT3 showed a prognostic value
with disease free, relapse-free and overall survival [74].
Finally, markers and gene expression proﬁles are
emerging for assessment of nodal metastasis. In the future,
these markers may be important as prognostic indicators
and diagnostic tools useful for decisions on elective neck
treatment (a particularly important issue in oral cancer
management) [75].
Principles of oral cavity cancer management
The overwhelming majority of cancers involving the oral
cavity are squamous cell carcinomas. These cancers of the
oral cavity may be treated with either radiation, surgery or
combined therapy. Single modality therapy is usually
attempted for early stage and other suitable (stages I, II and
selected stage III) tumors. Multimodality therapy is usually
employed for more advanced tumors.
Early disease
Superﬁcial carcinomas of the oral cavity can be treated
with equivalent excellent cure rates with either radiation
therapy (interstitial or external) or surgical excision.
Therefore, the choice of therapy is often based on the
factors, such as patient preference, quality of life, cost,
convenience and patient compliance. As surgical cures can
often be achieved rapidly and with minimal morbidity,
surgery is often preferred for management of early cancers
of the oral cavity. Tumors involving the oral tongue can
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Although radiotherapy is often equally effective for the
treatment of early disease, the chances of long-term
sequelae including xerostomia, dysphagia and osteoradio-
necrosis are such that the treatment of choice will be sur-
gery in most cases. Another advantage of surgical therapy
is the shorter duration of treatment; surgical therapy
requires a single intervention while radiation therapy
requires daily therapy for 6–7 weeks. Therefore, radiation
therapy is usually reserved for those patients who are
unable to undergo surgery. Another alternative treatment
modality may be photodynamic therapy using laser illu-
mination of superﬁcial tumors after intravenous adminis-
tration of a photosensitizer. However, experience with this
modality is still limited [76].
Advanced disease
Advanced disease of the oral cavity is best managed with
multimodality therapy. Surgery with or without recon-
struction [77] coupled with preoperative or postoperative
radiation therapy is often utilized for advanced disease.
Although preoperative radiation has been employed in
some cases to decrease the tumor mass and, therefore,
facilitate ‘‘resectability’’ of the tumor, it is common prac-
tice to surgically resect the tumor based on the pre-radia-
tion margins, as islands of viable tumor may persist within
the initial peripheral margins. In addition, preoperative
radiation is associated with a higher rate of postoperative
complications. For these reasons, most centers perform
surgery followed by postoperative radiation [78].
Robbins et al. [79] have employed neoadjuvant intra-
arterial chemotherapy and radiation followed by limited
excision of the area of initial tumor. If residual cancer is
found, a ‘‘completion’’ radical resection with wide margins
around the area of the original tumor is performed. This
series showed a 64% disease-speciﬁc survival and 74%
locoregional control for stages II–IV disease after 56-
month median follow-up. However, this is single institution
data that must be validated by further study.
Although primary surgical management has been
advocated for advanced oral cavity cancers due to concerns
of safety and efﬁcacy of non-surgical approaches, partic-
ularly with cancers that involve bone, recent evidence
suggests that primary chemoradiotherapy may be an
effective treatment approach for selected patients with T4
lesions. Rates of locoregional control, survival and com-
plications are comparable to those associated with primary
surgical management and postoperative radiotherapy [80].
Another reason to choose chemoradiotherapy as a primary
treatment may be ‘‘functional irresectability’’, for example,
to avoid total glossectomy. However, the deﬁnition of
‘‘functional irresectability’’ is vague and may differ among
surgeons [81].
Postoperative radiation therapy with or without con-
comitant chemotherapy is reserved for those cases in which
the risk of recurrence is high. Deﬁning the ‘‘high-risk’’
patient has been a topic of controversy. However, it is
important to emphasize that the indications for postopera-
tive radiation therapy directed to the primary site are dif-
ferent than the indications for postoperative radiation
directed at the neck.
The goal of a surgical excision is to achieve a complete
resection of the tumor with free margins. In cases where
there are positive or close margins (tumor within 5 mm of
the surgical margin), surgical re-resection is recommended
if the original margins can still be properly identiﬁed and if
re-resection will not induce signiﬁcant functional disabili-
ties. In cases where a re-resection is performed and evi-
dence of microscopically positive margins remains or if re-
resection cannot be reliably performed, radiation therapy
directed at the primary site should be considered. This is
particularly the case with tumors showing perineural
growth or strongly invasive growth. Brachytherapy has
proven efﬁcacious in cases with close or positive margins,
particularly when re-excision cannot be easily accom-
plished [82].
In cases where there is neck disease staged N2 or
greater, or when histopathological examination demon-
strates unfavorable features (like capsular invasion of the
nodal metastases), postoperative radiation therapy for the
neck is warranted. The addition of cisplatin-based che-
motherapy is indicated in the presence of positive margins
in the primary tumor resection specimen, multiple lymph
node involvement or ECS in the neck dissection specimen
[83, 84].
Management of tumors invading the mandible
Tumors invading the mandible can be managed either with
a marginal or a segmental resection. The decision regard-
ing the optimal extent of mandibular resection is largely
dependent on the degree of invasion. It has been suggested
that tumor invasion of the periosteum or cortical bone,
without invasion of the medullary cortex, can be appro-
priately managed with a marginal resection. Tumors that
erode into the medullary canal (T4 lesions), however,
require a segmental resection. It has been shown that once
a tumor gains access to the medullary canal, tumor may
travel through the canal within the neurovascular bundle.
The inability to obtain frozen section assessment of the
mandible intraoperatively represents a management
dilemma because decalciﬁcation of the mandible specimen
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take as long as 2 weeks.
The periosteum is relatively resistant to cancer invasion.
With the exception of the alveoli, the periosteum acts as a
dense barrier to the invasion of adjacent tumor. Despite the
protective periosteum, aggressive and longstanding tumors
erode and invade the adjacent mandible through a variety
of pathways. Two distinct histological patterns of tumor
invasion have been identiﬁed. The ﬁrst is referred to as
inﬁltrative, and is characterized by ﬁnger-like projections
of tumor that advance independently, invade the cancellous
spaces without the intervening connective tissue layer, and
possess not much osteoclastic activity. The second pattern
is referred to as erosive. In contrast to the inﬁltrative pat-
tern, the erosive pattern is characterized by a broad front
with a connective tissue layer and vigorous osteoclastic
activity. The differing signiﬁcance of the erosive and
inﬁltrative patterns has been conﬁrmed in several reports,
and it has been demonstrated that patient survival is sig-
niﬁcantly impacted by the pattern of invasion. Wong et al.
[85] found that the 3-year disease-free survival for squa-
mous cell carcinoma invading mandible with an inﬁltrative
pattern was 30%, while 3-year disease-free survival for the
erosive pattern was 73%. It has been suggested that the
pattern of invasion is a reﬂection of the biologic aggres-
siveness of the tumor and may impact the approach to
ablative therapy. While most tumors that invade the man-
dible mandate postoperative external beam radiation, it has
been suggested that superﬁcially invading tumors may not
beneﬁt from postoperative radiation. When considering the
aggressive behavior of the inﬁltrative pattern of invasion,
we recommend postoperative radiation for all patients with
this pattern of bone invasion.
Tumor within the oral cavity may invade the mandible
and gain entrance into the mandibular canal through sev-
eral routes. Not uncommonly, tumor will travel along the
surface mucosa until it approaches the attached gingiva
where the tumor cells may come into contact with the
periosteum of the mandible. Tumor cells demonstrate a
tendency to migrate into the alveoli because this area
represents a pathway of minimal resistance. In edentulous
patients, tumor cells will migrate onto the occlusal surface
of the alveolus and enter the mandible through dental pits,
which are cortical bone defects at the location of prior
dentition. Less commonly, tumor may enter the mandible
through mental or mandibular canals. Finally, adjacent
tumor may erode through the cortical bone directly into the
mandibular canal. As mentioned earlier, this is a rare mode
of invasion.
Determining the presence of bone erosion and the extent
of bone invasion represents an ongoing clinical dilemma.
The poor predictability associated with preoperative
imaging has led many to rely on preoperative clinical
assessment as the primary method for determining the
presence of mandibular invasion. Several groups have
studied this issue and found that clinical evaluation of
mandibular bone erosion is more sensitive than radio-
graphic evaluation; however, radiographic assessment may
be more speciﬁc and provide a higher reliability index [86].
There are a few studies reviewing the impact of clinical
assessment alone in determining the extent of mandibular
invasion. This likely represents the difﬁculty in quantifying
a clinical examination. However, most agree that clinical
assessment for invasion is paramount. Several studies have
evaluated the role of periosteal stripping as an indicator for
tumor invasion of the mandible and found that periosteal
stripping at the time of resection represented an accurate
predictor of the presence of mandibular invasion [42].
Without clear preoperative evidence of mandibular inva-
sion, a marginal resection followed by periosteal stripping
and inspection is an adequate approach. In the event that
microscopic evidence of invasion at the rim is discovered,
the marginal mandibulectomy is converted into a seg-
mental mandibulectomy.
Often, marginal mandibulectomy is performed not
because of suspicion of mandibular invasion, but to obtain
a wider margin of resection, and also, to achieve deeper
exposure and level of resection in the ﬂoor of the mouth. In
addition, marginal mandibulectomy may be helpful for
intraoral resurfacing, particularly if local tissues are
employed. Protrusion of uncovered bone through the suture
line is thus avoided.
In summary, appropriate preoperative assessment
through the combination of clinical and radiological
examination is more accurate than using either modality
alone. Intraoperative periosteal stripping at the time of
resection, with frozen section evaluation, represents an
accurate predictor of the presence of mandibular invasion
and may be the only reliable method of assessment.
Management of tumors invading the buccal mucosa
Buccal cancer comprises\10% of oral cavity cancers and
when it occurs, it commonly arises from pre-existing leu-
koplakia [87, 88]. The principles of management of buccal
cancer are no different than those of other subsites within
the oral cavity, with surgical therapy as the preferred
method of management. In early disease, surgical excision
can usually be accomplished transorally. Tumors that
invade the buccinator muscle and tumors that present with
nodal disease or with poor prognostic features should be
managed with postoperative irradiation. Negative surgical
margins are paramount, and in an effort to achieve this
goal, careful preoperative planning is essential to deter-
mine the extent of the tumor. MRI is ideal for imaging of
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Although early tumors of the buccal mucosa commonly
present as an irregular mucosal mass, more than half of
buccal tumors will present as deeply invasive tumors that
may track along the parotid duct, masseter muscle or into
the palate. The proximity of the buccal mucosa to the
parotid duct requires that the duct be traced retrograde and
sampled to ensure a negative margin.
Deeply invasive lesions may break into the buccal fat
pad. When this occurs, it is advisable to resect the entire
fat pad because negative surgical margins in this area are
difﬁcult to conﬁrm. The rich lymphatic network charac-
teristic of the buccal region and the high rate of lymph
node metastasis mandate that the neck be carefully eval-
uated and, in most cases, treated. Smaller tumors can
usually be managed through a transoral approach; how-
ever, more advanced tumors may require a midline labi-
otomy incision.
Management of tumors involving the hard palate
Unlike other areas of the oral cavity where squamous cell
carcinoma constitutes the overwhelming majority of
neoplasia, the palate is rich in minor salivary glands and
therefore is the frequent site of both benign and malignant
salivary gland tumors. The principles of management of
tumors of the palate are similar to those of the mandible;
obtaining tumor-free margins is essential to achieve a
good outcome. Preoperative imaging of this area is
important to assess invasion of the maxillary sinus, palatal
bone and the nasal vault. CT is ideal for assessing this
because it offers a high-resolution image of the palatal
and nasal bones. Lateral tumors may present a risk of
invasion and perineural spread via the palatine or tri-
geminal neurovascular bundle. Pain or anesthesia may
suggest nerve invasion and MRI with gadolinium may
demonstrate enhancement or edema of the nerve sug-
gesting nerve invasion. The depth of invasion will dictate
the extent of the surgical resection. Superﬁcial lesions of
the palatal mucosa are best managed with a wide surgical
resection including the underlying palatal periosteum. The
periosteum serves as an early barrier to spread. However,
as tumors become more invasive, tumors can vertically
invade the nasal vault or maxillary sinus, thus requiring
resection of underlying bone, and deeper (superior)
structures as necessary.
Minor salivary gland tumors of the hard palate rarely
metastasize to the neck and, therefore, a neck dissection is
rarely warranted in the absence of demonstrable regional
disease. One exception is when there is tumor erosion
through the posterior or posterior lateral maxillary sinus
into the ptyeryogpalatine fossa. Squamous cell carcinomas
of the hard palate, when they do metastasize, have a pre-
dilection to metastasize to level I; and this region should be
evaluated radiographically, or surgically by sentinel lymph
node biopsy or level I dissection, particularly for T2-stage
or larger tumors.
Management of tumors invading the ﬂoor of mouth
The ﬂoor of the mouth is rich in neural and vascular
structures including the lingual and hypoglossal nerves, the
submandibular duct, and the sublingual glands. The lack of
any substantial fascial barrier means that early tumors of
the ﬂoor of mouth can quickly invade in to the underlying
structures and metastasize to the ﬁrst echelon lymph node
basin. A careful preoperative clinical examination may
reveal information such as submandibular sialoadenitis or
lingual atrophy that may suggest submandibular duct or
hypoglossal nerve invasion, respectively. The MRI is ideal
for imaging the ﬂoor of mouth because it is accurate in
identifying soft tissue and perineural invasion.
Because of the density of neurovascular structures in the
ﬂoor of the mouth, frequent metastasis occurs to the sub-
lingual, submandibular and level II lymph node basins.
Sessions et al. [89] reviewed 280 cases and found a sig-
niﬁcant reduction in 5-year survival in the patients with
involved margins, advanced clinical tumor stage, positive
nodes and tumor recurrence. These authors suggested that
patients without clinically positive nodes can be observed
safely for regional nodal disease because subsequent
positive nodes can be effectively treated with no adverse
effect on survival. Others have found that a more aggres-
sive approach to the N0 neck is warranted and that a
selective neck dissection allows for early removal of occult
metastases with acceptable morbidity [90, 91]. Hicks et al.
[91] found that as many as 21% of patients with T1 lesions
or greater had occult metastatic disease and suggested an
elective neck dissection and adjuvant radiotherapy for
increased regional control for advanced tumors. However,
concerning the incidence of occult metastasis, much
depends on the diagnostic means that have been used for
pretreatment assessment of the neck and for the detection
of metastasis in the dissection specimen as mentioned
earlier in this paper.
Reconstruction of extensive defects
Extensive oral cavity tumors pose a surgical challenge
because of the potential for severe masticatory, speech and
swallowing disturbances, and life-threatening aspiration.
Patients may also suffer disﬁgurement following mandib-
ulectomy, particularly when it affects the anterior segment.
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for mandible reconstruction that should be performed at the
time of the segmental mandible resection. Four donor sites
(ﬁbula, iliac crest, radial forearm and scapula) have
become the primary sources of vascularized bone and soft
tissue for the reconstruction. The ﬁbula is the ﬁrst choice
for most defects, particularly those with anterior or large
bony defects [92, 93]. The use of an alternative donor site
is best reserved for cases with large soft tissue and minimal
bone requirements. Dental rehabilitation with osteointe-
grated dental implants is an important part of the recon-
structive process.
Mandibular reconstructions using titanium mesh sys-
tems with particulate cancellous bone and marrow har-
vested from the ilium, or by means of autogenous non-
vascularized iliac crest bone grafts are usually performed in
a second stage and present a high recipient-site complica-
tions rate. These methods are only useful when the defect is
lateral and only an extraoral approach is used [94]. The free
ﬂap success rate is close to 100%, and unrestricted or soft
diet can be achieved in nearly 90% of patients, whereas
speech is normal or near normal in two-thirds of patients
[92].
For locally advanced tumors, adequate resection neces-
sitates near total or total glossectomy. The tongue is
usually reconstructed with a rectus abdominis musculocu-
taneous-free ﬂap, but postoperative functional results in
terms of deglutition and speech are often poor due to the
lack of mobility of the ﬂap. Furthermore, additional
resection of the epiglottis combined with total glossectomy
causes severe aspiration and recurrent pneumonia. A
functional ‘‘neotongue’’ following total glossectomy
requires both soft tissue bulk and reconstruction of muscle
function. To achieve this goal, the innervated transverse
gracilis musculocutaneous ﬂap has been proposed [95].
The obturator nerve to the gracilis muscle is microsurgi-
cally sutured to the hypoglossal nerve to re-innervate the
gracilis muscle and the cutaneous paddle of the gracilis ﬂap
easily supplies enough bulk to replace the defect. This
procedure although providing adequate glossopalatal con-
tact and tongue movements, still does not achieve normal
tongue appearance and has no intrinsic secretory capability.
To circumvent this problem, in addition to the gracilis
muscle ﬂap, a free stomach ﬂap, with mucosal surface in-
traorally, has been used as an added source of secretion for
dry mouth with attached omentum providing adequate bulk
[96].
Oral cavity defects involving several areas may not be
amenable to reconstruction with a single free ﬂap. In
selected cases, multiple free ﬂap reconstruction has been
advocated to maximize quality of life even in patients with
advanced cancers, particularly when the patient has
received a mandibulectomy and total glossectomy [97].
Finally, for dramatic conditions in which as result of
extensive surgery and postsurgical and postradiotherapy
complications a patient is extremely disﬁgured and dis-
abled for elementary vital functions, the recently reported
technique of facial transplantation, with composite struc-
tures, may open a new frontier [98].
Management of the neck
The incidence of occult cervical metastasis in oral cavity
cancer, even in early stages varies from 6 to 46% [99],
necessitating elective treatment of the neck in the majority
of cases. The reason for the variance in reported incidence
of metastasis may be the differences in diagnostic tools that
have been used for preoperative assessment of the neck and
the differences in thoroughness of ﬁnding nodal metastasis
with histopathologic examination or other techniques for
evaluating the neck dissection specimen. Traditional tech-
niques of pathological analysis of neck dissections may fail
to detect isolated neoplastic cells and micrometastasis
[100, 101]. There is no method of pretreatment imaging or
other examination that will detect microscopic foci of
metastatic disease in cervical lymph nodes. Immunohisto-
chemical and molecular analysis of neck specimens reveals
the incidence of occult metastases to be higher than
revealed by light microscopy with ordinary hematoxylin
and eosin staining. Occult regional metastasis may be
found even in cases with small primary tumors.
Neck dissection
The neck may be treated electively by surgery or irradia-
tion. Surgery has the advantage of permitting pathological
staging of the neck, avoiding unnecessary radiation treat-
ment and indicating cases where adjuvant therapy should
be employed. As oral cavity cancer rarely metastasizes to
level V, a radical or modiﬁed radical neck dissection of all
ﬁve nodal levels is not necessary. Selective neck dissection
of levels I–III (‘‘supraomohyoid neck dissection’’) is the
procedure of choice for elective neck dissection of the
neck. Most of the relatively small numbers of isolated
metastasis to level IV are from primary tumors of the
tongue, which are known to produce ‘‘skip metastases.’’
Thus, an ‘‘extended supraomohyoid neck dissection’’ of
levels I-IV is recommended by some authors for elective
treatment of the neck in tongue cancer [102]. A number of
recent prospective multi-institutional studies have demon-
strated that sublevel IIB is rarely involved with isolated
metastasis from oral cavity primary tumors, except from
some tongue cancers [103–106]. Thus, it is justiﬁable to
omit dissection of sublevel IIB in elective treatment of
most cases of oral cavity cancers. Omitting sublevel IIB
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Also, a recently published systematic review and meta-
analysis of sublevel IIB metastasis in squamous cell car-
cinoma of the oral cavity [108] shows that isolated
metastases are uncommon at this sublevel. Bilateral neck
dissection should be performed in elective treatment of
tumors involving midline structures and in patients with
ipsilateral neck metastasis [109].
Generally, in tongue cancer, the incidence of nodal
metastasis depends upon the stage of the tumor. T1, T2 and
T3 tongue cancers are associated with 30, 50 and 70%
respective incidence of microscopic nodal metastasis.
Selective neck dissection can be used to effectively treat
clinically positive nodal disease in selected patients [110,
111]. The use of postoperative radiotherapy and concom-
itant chemotherapy should be considered in patients with
pathologically positive lymph nodes, particularly in cases
with adverse prognostic factors such as multiple metastatic
lymph nodes or any node with extracapsular disease. Two
prospective, randomized trials were reported in 2004
demonstrating improved survival and locoregional control
(as well as increased toxicity) when adjuvant chemora-
diotherapy was administered to patients with ECS or N2–3
disease [83, 84].
Sentinel lymph node biopsy
During the last decade, SLNB has evolved as a possible
replacement for elective neck dissection with promising
results [112, 113]. The reduced number of lymph nodes can
be assessed by step serial sections and immunohisto-
chemistry [114]. The work of Goerkem et al. [21] has been
discussed above.
SLNB is a technique well established for cutaneous
melanoma and breast cancer, and is under extensive study
by numerous groups for application to oral cavity cancer.
Preoperative lymphoscintigraphy allows assessment of the
individual lymphatic drainage pattern of each patient.
SLNB allows accurate staging of the ipsilateral neck in
clinically N0 cases, both necks in tumors crossing the
midline, and the contralateral neck in tumors crossing the
midline with ipsilateral positive nodes. The technique has
the potential of limiting the application of elective neck
dissection in 30–40% of patients who may beneﬁt from it,
reducing considerably the number of bilateral neck dis-
sections, and sparing the morbidity and costs of elective
neck dissection for those patients without regional disease
who cannot beneﬁt from neck dissection. The ﬁrst
promising validation studies of patients undergoing SLNB
followed by elective neck dissection were published
almost a decade ago by groups in Europe [114, 115].
Since then, many centers throughout the world have
adopted the technique. The American College of
Surgeons Oncologic Group (ACOSOG) has recently
completed a prospective validation trial and results are
forthcoming [116].
Most centers in Europe have moved a step forward to
observational trials. Based on the excellent results of two
large series showing a neck recurrence rate after negative
SLNB of \5%, a multicentric prospective observational
trial has been started [113, 117]. The accrual of patients
is almost completed and ﬁrst results may be expected
soon.
The technique of SLNB involves preoperative injection
of [99]
mTc sulfur colloid in several locations around and
immediately adjacent to the tumor in the awake patient
[118]. The importance of preoperative lymphoscintigra-
phy for the accurate detection of the sentinel nodes has
been reported by Ross et al. [119]. The use of isosulfan
blue dye (Lymphazurin 1%, Hirsch Industries Inc.,
Richmond VA) often used in cases of melanoma, has
been employed by some surgeons for oral cavity SNLB,
but was not used in the ACOSOG study, and is avoided
by many experienced surgeons to avoid discoloration of
tissues with obscuration of important structures and
mucosal margins and has other potential disadvantages,
such as anaphylaxis in a small number of patients [120].
Despite some practical difﬁculties, the sentinel node
detection rate approaches 100% once the ‘‘learning
curve’’ of 10–20 cases has been overcome. During sur-
gery, the gamma probe is used to scan the neck, and an
incision is made over the area of highest radioactivity. All
the active lymph nodes are then removed and sent to
pathology for evaluation. If metastatic disease is identi-
ﬁed, a neck dissection is performed. Otherwise, the neck
can be closed. There is still controversy on the advantages
and disadvantages of frozen sections. Several groups have
investigated the accuracy of frozen section analysis of
sentinel lymph nodes and, despite concerns regarding
freezing artifacts, loss of tissue and high expenditures of
labor and time, results have proven encouraging [121,
122]. The negative-predictive value of a negative SLNB
with frozen section is reported to be as high as 83%, with
only 17% of the frozen-section negative patients having to
undergo a second procedure due to false-negative frozen-
section examinations. In most cases, this was found to be
due to isolated tumor cells or minimal micrometastatic
disease [113]. If metastatic disease is identiﬁed postop-
eratively, a subsequent neck dissection is performed.
According to the recommendations of the second inter-
national conference on sentinel node biopsy for mucosal
head and neck cancer, the pathologic evaluation of the
sentinel lymph nodes should be done with serial step
sectioning at intervals of 150 lm, and in addition to
staining with hematoxylin and eosin, immunohistochem-
ical examination for cytokeratin is mandatory [123].
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may allow patients to avoid the additional time and mor-
bidity of a formal neck dissection, (2) it allows for a
minimally invasive assessment of lymph node status in
patients with low risk lesions for whom ‘‘watchful waiting’’
might otherwise be recommended, (3) it may detect
potentially involved nodes which are outside of the
expected lymphatic drainage patterns, (4) it may be an
alternative for patients who refuse a neck dissection.
The chief concern regarding SLNB for oral cavity
cancer is the possibility of false-negative diagnosis,
although this rate has been shown to be\5%, which is in
the range of elective neck dissection. In the ACOSOG
validation trial, a negative-predictive value of 93% was
seen on hematoxylin and eosin staining, 96% with serial
step sectioning and immunohistochemistry, and 100% for
T1 lesions [116]. Although the cohort was small, ﬂoor of
mouth tumors in the ACOSOG trial had a higher rate of
false negatives (25 vs. 8% for tongue primaries). The high
likelihood of metastatic disease in patients with T3 and T4
cancers as well as the difﬁculties with injecting around a
large tumor has limited the application of SLNB to T1 and
T2 oral cavity cancers.
Other problems with SLNB include the fact that
invariably in the neck there are multiple sentinel nodes. In
addition, the ‘‘shine-through effect’’ (obscuration of the
neck by irradiation from the primary tumor) creates some
difﬁculties in appropriately evaluating the sentinel node
during a surgical procedure. In addition, the low morbidity
of selective neck dissections discourages the use of a
technically demanding procedure to avoid them.
The current recommendations of the ACOSOG are that
SNLB can be offered to patients who would otherwise
not warrant a neck dissection (‘‘watchful waiters’’),
patients who refuse neck dissection, or those on a clinical
trial. In Europe, many centers have introduced SLNB as
the standard of care for T1 and T2 squamous cell car-
cinoma of the oral cavity with ‘‘elective neck’’ dissection
only in case of a positive SLNB (in which case, the neck
dissection is no longer ‘‘elective’’). Most of these centers
have joined the multicentric prospective trial in order to
collect data from a greater number of patients and in a
shorter time. Thus, it would seem that currently the
SLNB is most useful for upstaging apparently early
cancers of the oral cavity, thereby identifying patients
who might beneﬁt from additional surgical or adjuvant
therapy [124].
Particularly in the United States, a majority of surgeons
still prefer a staging supraomohyoid neck dissection rather
than SLNB, for the reasons cited above. A decision-anal-
ysis model comparing the performance of SLNB with
elective neck dissection showed better outcomes with
elective neck dissection over a range of micrometastasis
rates from 20 to 40% [125]. Therefore, SLNB cannot be
considered a standard of care at this stage [126].
‘‘Watchful waiting’’
Finally,anotherstrategyconcerningtheneckinpatientswith
small and superﬁcial oral cancers may be a ‘‘watchful wait-
ing’’ policy. In these patients, the neck will be closely
observed in follow-up, usually using ultrasonography of the
neck,insteadofperforminganelectiveneckdissection[127].
Postoperative surveillance
The risk of recurrence or the development of a new primary
warrants close follow-up for all individuals treated for oral
cavity cancer. Most recommend follow-up examinations
every 2–3 months for the ﬁrst year, 3–4 months for the
second year, 4 months for the third year, and 5 months for
the fourth and ﬁfth years. Thereafter, patients are followed
every 12 months. High-risk patients may be monitored
more often while low risk patients may be monitored less
frequently. Regular follow-up for over 10 years is indi-
cated for all patients treated for cancer of the oral cavity
[128].
Conclusions
Oral cavity cancers represent about one-third of head and
neck malignant tumors and present unique challenges for
optimal management to limit morbidity and maximize the
chance for cure. The great majority are squamous cell
carcinomas with a minority being mucoepidermoid or other
minor salivary gland tumors. Tobacco remains the most
common causative factor. HPV is strongly associated with
the development of oropharyngeal cancer and a small
minority of oral cavity cancers. Identiﬁcation of oral cavity
cancers is relatively simple given the ease of a clinical
examination; therefore, screening programs and/or educa-
tional programs may be considered. The development of
leukoplakia, erythroplasia, a mass or an ulcer should
prompt thorough evaluation by a head and neck surgeon
and most likely a transoral biopsy.
Prognosis of oral cavity cancer is generally related to the
TNM classiﬁcation system. However, patient-related fac-
tors, such as co-morbidity and tumor-related factors, such
as perineural invasion, depth of invasion or extracapsular
nodal spread are related to prognosis or may be strongly
predictive of biologic behavior of the tumor as well. Initial
search and follow-up surveillance for synchronous and
metachronous squamous cell carcinomas may have an even
greater impact on patient outcome.
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subsequent evaluation includes imaging, though which
modality to employ is controversial. CT and MRI are
comparable in their ability to stage cancers of the oral
cavity. MRI in particular is excellent for soft tissue eval-
uation and for a contrast study in patients with a contra-
indication to intravenous administration of iodine
containing contrast. However, clinical examination both
preoperative and intraoperative may still be the best way to
assess tumor invasion into the mandible.
Early disease (stages I–II) is generally curable with
single modality therapy. Surgery is preferable in most cases
due to the simplicity of the treatment and excellent results
with respect to cure and postoperative function. Advanced
disease (stages III–IV) is best managed with multimodality
therapy, generally with surgery followed by radiotherapy
particularly for high-risk primary lesions. Adjuvant che-
moradiotherapy to the neck is indicated for N2 or greater
disease, or N1 disease with ECS. Primary chemoradiation
may be considered in cases which are technically or
‘‘functionally’’ inoperable.
Tumors invading the mandible are generally managed
with segmental resection. Marginal resection, indicated
when suitable if it can be shown that the tumor does not
invade the medullary canal, is often employed to enhance
tumor margins, improve access and facilitate reconstruc-
tion. Most tumors that invade the mandible require post-
operative radiotherapy for improved local control.
There is a high incidence of cervical metastases in oral
cavity cancer. For all but very early primary tumors,
elective treatment of the neck with either radiation or
neck dissection is warranted to optimize regional control.
Surgical treatment of the neck is generally preferable to
radiation as it offers pathologic information, has limited
morbidity, avoids the lengthy treatment regimen and
morbidity of radiation. Sublevel IIB and level V are rarely
involved with tumor, and therefore, elective neck dis-
section can generally be done without violating these
regions.
SLNB for T1 and T2 cancers has been successfully
evaluated in many trials all over the world. Its potential as a
new standard of care is currently being widely studied in
prospective clinical trials.
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